ERBB2 and gastroesophageal junction adenocarcinoma: Cost‐Effectiveness of Pembrolizumab Plus Trastuzumab and Chemotherapy Versus Trastuzumab Plus Chemotherapy as First‐Line Treatment of HER2‐Positive Gastric or Gastroesophageal Junction Adenocarcinoma in China